Australia Becomes the First in the World to Permit NMN for Use in Listed Medicines
Longevity Life Sciences (LLS) is honoured to announce that Nicotinamide Mononucleotide (NMN) has been formally added to the Therapeutic Goods Administration (TGA) Permissible Ingredients Determination — making Australia the first country in the world to permit NMN for use in Listed Medicines.
This landmark regulatory decision represents a defining moment for the field of NAD+ science. It establishes Australia as the global leader in setting a rigorous, pharmaceutical-grade framework for NMN — a distinction unmatched by any other jurisdiction to date.
Following this decision, LLS is currently the only authorised supplier of NMN for use in Listed Medicines in Australia via our flagship ingredient, CellVive NMN®.
This outcome reflects years of scientific collaboration, regulatory engagement, and our commitment to building the highest standards of evidence-based NAD+ innovation.
Why This Matters
- The world’s first regulated, therapeutic-grade access pathway for NMN
- Legally compliant, transparent supply for Australian consumers
- Pharmaceutical-grade quality, purity, and manufacturing standards
- Evidence-aligned claims under TGA oversight
Australia Sets the Global Benchmark
Australia becomes the first country globally to formally recognise and regulate NMN within a therapeutic framework.
Canada has taken steps toward regulating NMN within natural health products — however, Australia is the first to enshrine NMN within a therapeutic, pharmaceutical-grade category.
This milestone validates the rigorous scientific, regulatory and manufacturing foundations LLS has established in partnership with SyncoZymes in Shanghai, global leaders in enzymatically synthesised, high-purity NMN.
A New Chapter for Evidence-Based NAD+ Innovation
- Regulated NMN supply
- High-purity NAD⁺ restoration ingredients
- Guiding future clinical research and therapeutic development
- Responsible innovation grounded in science and safety
